Bicycle Therapeutics (United Kingdom)

company in Cambridge, United Kingdom

BCYC Nasdaq ISIN US0887861088 SEC CIK 1761612 LEI 213800XKUI6R7GKC3E43
Follow Bicycle Therapeutics (United Kingdom) Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $34.1M +190.2% vs same quarter last year
Net income −$10.5M +82.3% vs same quarter last year
EPS, diluted −$0.15 +82.4% vs same quarter last year
Operating cash flow −$40.3M +43.4% vs same quarter last year
Revenue by quarter
$3.7M
$10M
$2.9M
$11.7M
$48M
$887K
$629K
$34.1M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
  • Revenue
  • Net income
−$300M−$200M−$100M$0$100MFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$72.6M−$219M
FY24$35.3M−$169M
FY23$27M−$180.7M
FY22$14.5M−$112.7M
FY21$11.7M−$66.8M
FY20$10.4M−$51M
FY19$13.8M−$30.6M
FY18$7.1M−$21.8M
FY17$2.1M−$16.3M
FY16--
MarginsShare of revenue
  • Operating margin
  • Net margin
−1000%−750%−500%−250%0%FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−340.4%−301.7%
FY24−595%−479.2%
FY23−704.1%−669.7%
FY22−806.6%−779.3%
FY21−561%−571.2%
FY20−500.1%−491%
FY19−190.6%−221.8%
FY18−304.7%−306.1%
FY17−787%−789.3%
FY16--
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$252M
FY24−$166M
FY23−$63.6M
FY22−$105.1M
FY21−$16.8M
FY20−$19M
FY19−$30.2M
FY18−$27.3M
FY17−$2.5M
FY16-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Bicycle Therapeutics (United Kingdom)
  • Healthcare median
−800%−600%−400%−200%0%FY17FY19FY21FY23FY25
Show the numbers
YearBicycle Therapeutics (United Kingdom)Healthcare median
FY25−301.7%−30.6%
FY24−479.2%−47%
FY23−669.7%−58%
FY22−779.3%−80.4%
FY21−571.2%−71.9%
FY20−491%−62.2%
FY19−221.8%−46.3%
FY18−306.1%−49.6%
FY17−789.3%−45.9%
FY16-−36%